{"id":"NCT02032901","sponsor":"Bristol-Myers Squibb","briefTitle":"Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV","officialTitle":"A Phase 3 Evaluation of Daclatasvir and Sofosbuvir in Treatment Naive and Treatment Experienced Subjects With Genotype 3 Chronic Hepatitis C Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01","primaryCompletion":"2014-09","completion":"2014-12","firstPosted":"2014-01-10","resultsPosted":"2015-09-14","lastUpdate":"2015-10-01"},"enrollment":173,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"Daclatasvir","otherNames":["BMS-790052"]},{"type":"DRUG","name":"Sofosbuvir","otherNames":[]}],"arms":[{"label":"A1:Daclatasvir + Sofosbuvir in treatment-naive subjects","type":"EXPERIMENTAL"},{"label":"A2:Daclatasvir + Sofosbuvir in treatment-experienced subjects","type":"EXPERIMENTAL"}],"summary":"To study the combination of Daclatasvir and Sofosbuvir for the treatment of hepatitis C virus (HCV) Genotype 3 infection","primaryOutcome":{"measure":"Percentage of Treatment-Naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) Target Detected (TD) or Target Not Detected (TND)","timeFrame":"Week 12 (Follow-up period)","effectByArm":[{"arm":"Daclatasvir + Sofosbuvir in Treatment-naive Participants","deltaMin":90.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":31,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["27188960","25614962"],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":152},"commonTop":["Headache","Fatigue","Nausea","Diarrhoea","Insomnia"]}}